Enzymatic characteristics of CYP3A5 and CYP3A4:: A comparison of in vitro kinetic and drug-drug interaction patterns

被引:41
|
作者
Emoto, C. [1 ]
Iwasaki, K. [1 ]
机构
[1] Pfizer Japan Inc, Dept Pharmacokinet Dynam Metab, Nagoya Labs, Aichi 4702393, Japan
关键词
CYP3A4; CYP3A5; alpha-naphthoflavone; interaction;
D O I
10.1080/00498250500489968
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
CYP3A4 and CYP3A5 exhibit significant overlap in substrate specificity, but can differ in catalytic activity and regioselectivity. To investigate their characteristics further, the enzymatic reactions of the two CYP3A enzymes were compared using midazolam, nifedipine, testosterone and terfenadine as substrates. Both CYP3A5 and CYP3A4 showed sigmoid and substrate inhibition patterns for testosterone 6 beta-hydroxylation and terfenadine t-butylhydroxylation (TFDOH), respectively. In the other reactions, the kinetic model for CYP3A5 was not similar to that for CYP3A4. An inhibition study demonstrated that the interactions between alpha-naphthoflavone (alpha NF) and CYP3A substrates were different for the two CYP3A enzymes. alpha NF stimulated nifedipine oxidation catalysed by CYP3A5, but did not stimulate that catalysed by CYP3A4. alpha NF at less than 32 mu M inhibited TFDOH catalysed by CYP3A5, but did not inhibit that catalysed by CYP3A4. These results indicate that CYP3A5 has different enzymatic characteristics from CYP3A4 in some CYP3A catalysed reactions.
引用
收藏
页码:219 / 233
页数:15
相关论文
共 50 条
  • [31] Domperidone as a substrate marker drug for CYP3A4 and CYP3A5.
    Michaud, V
    Simard, C
    Morin, N
    Turgeon, J
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (02) : P47 - P47
  • [32] Differential drug-induced mRNA expression of human CYP3A4 compared to CYP3A5, CYP3A7 and CYP3A43
    Krusekopf, S
    Roots, I
    Kleeberg, U
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2003, 466 (1-2) : 7 - 12
  • [33] Screening of Genetic Polymorphisms of CYP3A4 and CYP3A5 Genes
    Leel, Jin Sol
    Cheong, Hyun Sub
    Kim, Lyoung Hyo
    Kixn, Ji On
    Seo, Doo Won
    Kim, Young Hoon
    Chung, Myeon Woo
    Han, Soon Young
    Shin, Hyoung Doo
    KOREAN JOURNAL OF PHYSIOLOGY & PHARMACOLOGY, 2013, 17 (06): : 479 - 484
  • [34] NEW TOOLS TO DIFFERENTIATE CYP3A4 AND CYP3A5 ACTIVITY
    Li, Xiaohai
    Kamenecka, Theodore M.
    Jeso, Valer
    Micalizio, Glen
    Heyward, Scott
    Walker, Gregory S.
    Cameron, Michael D.
    DRUG METABOLISM REVIEWS, 2015, 47 : 70 - 70
  • [35] The relative role of CYP3A4 and CYP3A5 in eplerenone metabolism
    McGraw, Joseph
    Cherney, Mitchell
    Bichler, Katherine
    Gerhardt, Armin
    Nauman, Mirielle
    TOXICOLOGY LETTERS, 2019, 315 : 9 - 13
  • [36] Differential inhibition of CYP3A4 and CYP3A5 by verapamil.
    Wang, Y
    Jones, DR
    Hall, SD
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (02) : P16 - P16
  • [37] GLOBAL ANALYSIS OF CYP3A4 AND CYP3A5 GENOTYPE ON IN VIVO CLEARANCE OF CYP3A4 SUBSTRATES.
    Quinney, S. K.
    Schwartz, J. B.
    Hall, S. D.
    Gorski, J. C.
    Li, L.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 91 : S49 - S49
  • [38] Cyclosporine A- and Tacrolimus-Mediated Inhibition of CYP3A4 and CYP3A5 In Vitro
    Amundsen, Rune
    Asberg, Anders
    Ohm, Ingrid Kristine
    Christensen, Hege
    DRUG METABOLISM AND DISPOSITION, 2012, 40 (04) : 655 - 661
  • [39] The Relative Contributions of CYP3A4 and CYP3A5 to the Metabolism of Vinorelbine
    Topletz, Ariel R.
    Dennison, Jennifer B.
    Barbuch, Robert J.
    Hadden, Chad E.
    Hall, Stephen D.
    Renbarger, Jamie L.
    DRUG METABOLISM AND DISPOSITION, 2013, 41 (09) : 1651 - 1661
  • [40] Selective expression of CYP3A5 and not CYP3A4 in human blood
    Janardan, SK
    Lown, KS
    SchmiedlinRen, P
    Thummel, KE
    Watkins, PB
    PHARMACOGENETICS, 1996, 6 (05): : 379 - 385